Phase I Study of KPT330 in Asian Patients

NCT ID: NCT02078349

Last Updated: 2020-09-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2020-03-20

Brief Summary

This is an open-label, dose-escalation (Phase 1a) and expansion (Phase 1b) study to evaluate the safety and tolerability of KPT-330 and determine the recommended phase 2 dose (RP2D) in patients with solid tumor malignancies. The study drug KPT-330 or Selinexor works by blocking high levels of exporter proteins in cancer cells so that the tumor suppressor proteins (TSP, proteins that help to protect cells from becoming cancerous) and growth regulatory proteins (GRP, proteins that help control the growth of cells) will remain in the nucleus in its "activated" form. The idea for using this drug is that the blockage of this export of proteins from the nucleus should result in stopping the growth of tumor cells. Based on its mechanism of action, KPT-330 is a new class of drug called Selective Inhibitor of Nuclear Export (SINE).

The purposes of this research study are to find out more information about the drug such as: the highest dose of KPT-330 that can be given safely, the side effects it may cause, to examine how the body affects the study drug concentrations in the blood (called pharmacokinetics or PK), to examine the effects of this study drug on the body (called pharmacodynamics or PD) and to gain some information on its usefulness in treating cancer.

Benefits of the study include the chance of disease control for patients with treatment refractory cancer for which no other standard treatments are available. Common side effects (35-73%) in humans have mostly been mild and reversible. These include nausea, loss of appetite, fatigue, vomiting and weight loss.

Detailed Description

This is a single-centre, phase 1a (dose escalation) and 1b (doses expansion) study to evaluate the safety and tolerability of oral Selinexor in Asian patients with advanced solid malignancies. After the initial screening visit and registration in the study, each patient will be assigned to 3 different schedules, a starting dose of 50 mg/m2 (Schedule 1) given once weekly ; 40 mg/m2 (Schedule 2) with a twice weekly dosing schedule and three times a week at 20mg/m2 (Schedule 3) dosing schedule have been chosen for this study. For Schedule 2, drug administration will occur twice weekly, on days 1 and 3 of the first two weeks (e.g. Monday and Wednesday or Tuesday and Thursday) and for Schedule 3, drug administration will occur three times a week on days 1, 3 and 5 (ie: Monday, Wednesday and Friday). For Schedule 1, one cycle is 4 weeks with 4 doses of Selinexor. In Schedule 2, one cycle is 3 weeks with 4 doses of Selinexor. In Schedule 3, one cycle is 4 weeks with 12 doses of Selinexor. Dose will be escalated using a 3+3 design. Patients who have difficulty tolerating treatment (e.g., due to anorexia, nausea, or fatigue) at any dose level may have their dose reduced by 4-10 mg/m(2) increments to a lowest dose of 11 mg/m(2). Aggressive use of supportive medications is often sufficient to mitigate or eliminate tolerability problems.Supportive care including antinausea/ anti-emetic therapy, acid suppression (H2-blockers and/or proton pump inhibitors), glucocorticoids, anti-diarrheal therapy, and other standard treatments may be administered as per institutional guidelines both prophylactically and for symptomatic patients. A 3+3 design will be used for the dose escalation. A minimum of 3 patients will be enrolled per cohort. Once 3 patients are enrolled in a cohort and have completed at least six days of dosing at the target dose, up to 3 additional patients may be added to that cohort. After up to 6 patients have been accrued to a dose level, that dose level will be closed to accrual until safety assessment of all the 3 to 6 patients is performed through a safety cohort meeting at the end of cycle 1. If the dose level is well tolerated during these 4 weeks at the target dose, then dose escalation will be performed in the next cohort. Dose escalation in the 3+3 design will proceed as follows:

• At least 3 patients will be entered into the cohort. Once 3 patients are enrolled in a cohort and have completed at least six days of dosing at the target dose, up to 3 additional patients may be added to that cohort.
• If none of the patients in this cohort experience DLT during the 4 weeks at the target dose, dose escalation will be continued as per protocol design
• If one of patients experiences first cycle DLT, up to three additional patients will be added to this cohort (maximum 6 will be evaluated in this cohort) and if no additional patients experience DLT (i.e. only 1 out of 6 patients in the cohort experience DLT), dose escalation as per protocol will be allowed.
• If a DLT is observed in 2 or more subjects in a cohort of 3 or 6 subjects at a dose level, and a lower dose level has not been tested, then an additional 3 subjects will be enrolled at a lower dose level.
• If, following dose escalation, 2 patients in the cohort experience first cycle DLT, this dose will be labelled as Maximally Tolerated Dose (MTD) and the RP2D will be the previous dose at which <= 1/6 patients experienced a DLT. If only 3 subjects were treated at the previous lower dose level, then an additional 3 subjects will also be recruited for a total of 6 subjects at that dose level.
• However an additional cohort of patients may be enrolled at a dose between MTD and the dose below it. If dose level 3 is reached and criteria for determining MTD are not met, further dose escalation for each dose level may occur after discussion with the investigators, Karyopharm and the PI.If one patient in a cohort develops a DLT in Cycle 1, at least 5 additional patients will be enrolled at that dose level. If there are no additional DLTs at that dose level, then doses will be escalated by up to 30-40% and all subsequent cohorts will include >=3 patients. If one DLT occurs in the first 3 patients enrolled in a cohort, an additional 3 patients will be enrolled. If another DLT occurs at this dose level (i.e., 2 DLTs/6 patients), this dose will be considered the MTD, and the RP2D is defined as the dose level below this dose, provided that that dose level is <=25% lower than the highest (intolerable) dose tested. This protocol is designed to guide maximal escalation, while ensuring patient safety. In order to achieve this, during each safety cohort review meeting with the investigators, Karyopharm, and PI, a decision will be made on the dose escalation scheme.

The recommended phase 2 dose (RP2D) is defined as the next lower dose level below MTD. The MTD is the dose level in which > 1 of 3 patients or >= 2 of 6 patients experience DLT, provided that that dose level is <=25% lower than the highest (intolerable) dose tested. If the projected RP2D is > 25% lower than the highest dose tested, then an additional cohort of >=3 patients will be added at a dose that is intermediate between the intolerable dose and the next lower dose. Once RP2D is reached, approximately 60 patients may be enrolled in the Dose Expansion cohort. The dose schedule for the Dose Expansion Phase will be the same as that for the Dose Escalation Phase. There is no maximum duration of participation for any patient enrolled in this study. However it is anticipated that for patients remaining on study for prolonged periods, an Extension study protocol will be made available in the near future.The dose used in the expansion phases of the study will be the RP2D (or lower doses) as determined in the dose escalation phases of the study.

Conditions

Solid Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Solid Tumors

Patients will receive Selinexor once weekly (Schedule 1) or twice weekly (Schedule 2) or three times a week (Schedule 3) orally at a starting dose of 50 mg/m² (Schedule 1) and 40mg/m2 (Schedule 2) and 20mg/m2 (Schedule 3).

One cycle is 28 days for Schedule 1 and Schedule 3 and 21 days for Schedule 2. Treatment will continue until disease progression or the development of unacceptable toxicities.

Group Type: EXPERIMENTAL

KPT-330

Intervention Type: DRUG

Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.

Interventions

KPT-330

Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.

Intervention Type: DRUG

Other Intervention Names

Selinexor

Eligibility Criteria

Inclusion Criteria

• All patients must sign an informed consent in accordance with local institutional guidelines
• Age ≥ 21
• Dose Escalation Phase: Patients with histologically or cytologically confirmed advanced or metastatic solid tumors who have radiological evidence of progressive disease on study entry that is deemed unlikely to benefit from further conventional therapy, or for which no standard therapy is available.

Dose Expansion Phase: Patients with previously treated, metastatic or advanced recurrent malignancy (including gastric, colorectal, lung, head and neck and gynaecological malignancies) which has been confirmed histologically or cytologically, and who have evidence of progressive disease on study entry that is deemed unlikely to benefit from further conventional therapy, or for which no standard therapy is available. Depending on the total number of patients enrolled in the dose escalation phase, the number of patients recruited in the subsequent dose expansion phase may be adjusted accordingly.

Exclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 1;
• Patients must have adequate bone marrow function and organ function within 2 weeks of study treatment;

1. Adequate hematologic function defined as:

• platelets ≥ 125 x 109/L in dose escalation phase, and platelets ≥ 100 x 10(9)/L in dose expansion phase.
• hemoglobin ≥ 5.59 mmol/L or 9 g/dL,
• ANC ≥ 1.5 x 109/L,
• WBC ≥ 3.0 x 109/L.
• Up to 5% deviation is tolerated. Transfusions and growth factors are allowed prior to and throughout the study.

2. Hepatic function: bilirubin < 2.0 times the upper limit of normal (ULN), ALT < 2.5 times ULN

• Up to 10% deviation is acceptable

3. Adequate renal function: estimated creatinine clearance of ≥ 30 mL/min, calculated using the formula of Cockroft and Gault: (140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female.

4. Amylase and lipase ≤ 1.5 x ULN;

5. Alkaline phosphatase limit ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement of their cancer);

6. International normalization ratio (INR) (if not on anticoagulation therapy) and partial thromboplastin time (PTT) ≤ 1.5 x ULN;

• All patients (male and female) of childbearing potential must agree to use adequate birth control (barrier methods) during and for 3 months after participation in this study. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose.

• Patients with significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy;
• Radiation (except planned or ongoing palliative radiation to bone outside of the region of measurable disease) ≤ 3 weeks prior to cycle 1 day 1
• Chemotherapy, or immunotherapy or any other systemic anticancer therapy ≤ 3 weeks prior to cycle 1 day 1.
• Unstable cardiovascular function;
• Known HIV infection;
• Renal failure requiring haemodialysis or peritoneal dialysis;
• Clinically unstable, active infection requiring systemic antibiotics;
• Patients who are pregnant or breast-feeding;
• Concurrent cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years;
• Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral medications;
• Patients with serious psychiatric or medical conditions that could interfere with treatment.
• History of organ allograft within a period of 6 months or less prior to commencing study
• Concurrent therapy with approved or investigational anticancer therapeutics;
• Body weight significantly below ideal body weight in the opinion of the investigator
• Significant episode of bleeding in the last 4 weeks (e.g. hemorrhoids, epistaxis etc.)

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Karyopharm Therapeutics Inc

INDUSTRY

Sponsor Role: collaborator

National University Hospital, Singapore

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Boon Cher Goh, MBBS

Role: PRINCIPAL_INVESTIGATOR

National University Hospital, Singapore

Locations

National University Hospital

Singapore, , Singapore

Countries

Singapore

References

Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012 Apr 15;83(8):1021-32. doi: 10.1016/j.bcp.2011.12.016. Epub 2011 Dec 20.

Reference Type: BACKGROUND

PMID: 22209898 (View on PubMed)

Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K, Volarevic S, Oren M. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell. 2012 Jan 27;45(2):222-32. doi: 10.1016/j.molcel.2011.11.022.

Reference Type: BACKGROUND

PMID: 22284678 (View on PubMed)

Other Identifiers

2013/01034

Identifier Type: OTHER

Identifier Source: secondary_id

KPT330-A1

Identifier Type: -

Identifier Source: org_study_id